Legend Biotech (LEGN) Assets Average (2020 - 2026)

Legend Biotech (LEGN) has reported Assets Average for 7 consecutive years, with $1.7 billion the latest figure, recorded in Q1 2026.

• Quarterly Assets Average rose 1.36% year-over-year to $1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 1.36% YoY) and the FY2025 annual result came in at $1.7 billion, down 3.27% from the prior year.
• Assets Average eased to $1.7 billion in Q1 2026 per LEGN's latest filing, from $1.7 billion in the prior quarter.
• Over the last five years, Assets Average for LEGN reached as high as $1.9 billion in Q3 2023 and fell as low as $1.1 billion in Q1 2022.
• A 5-year average of $1.7 billion and a median of $1.7 billion in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average tumbled 99.65% — and 2024, when it jumped 42.65%.
• Year by year, Assets Average stood at $1.1 billion in 2022, then surged by 70.45% to $1.8 billion in 2023, then dropped by 7.64% to $1.7 billion in 2024, then rose by 1.19% to $1.7 billion in 2025, then dropped by 3.37% to $1.7 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $1.7 billion, $1.7 billion, and $1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.